Protagonist Therapeutics Announces Data From Phase 2 Rusfertide Study In Hereditary Hemochromatosis Selected For Oral Presentation At The Annual AASLD Meeting
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary